{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T18:40:48Z","timestamp":1771526448442,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2007,11,1]],"date-time":"2007-11-01T00:00:00Z","timestamp":1193875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2007,11]]},"DOI":"10.1016\/j.jinf.2007.07.012","type":"journal-article","created":{"date-parts":[[2007,9,8]],"date-time":"2007-09-08T07:19:33Z","timestamp":1189235973000},"page":"408-413","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Teicoplanin levels in bone and joint infections: Are standard doses subtherapeutic?"],"prefix":"10.1016","volume":"55","author":[{"given":"Philippa C.","family":"Matthews","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivor","family":"Byren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bridget L.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2007.07.012_bib1","first-page":"185","article-title":"Serum and bone concentrations of teicoplanin and vancomycin: study in an animal model","volume":"24","author":"Drago","year":"1998","journal-title":"Drugs Exp Clin Res"},{"key":"10.1016\/j.jinf.2007.07.012_bib2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1469-0691.2004.00747.x","article-title":"The use and therapeutic drug monitoring of teicoplanin in the UK","volume":"10","author":"Darley","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jinf.2007.07.012_bib3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/jac\/dkg061","article-title":"Cost-minimization analysis and audit of antibiotic management of bone and joint infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid therapy","volume":"51","author":"Nathwani","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2007.07.012_bib4","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/BF01690746","article-title":"Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis","volume":"14","author":"Graninger","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2007.07.012_bib5","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1179\/joc.2000.12.5.412","article-title":"Long-term intramuscular teicoplanin treatment of chronic osteomyelitis due to oxacillin-resistant Staphylococcus aureus in outpatients","volume":"12","author":"Testore","year":"2000","journal-title":"J Chemother"},{"key":"10.1016\/j.jinf.2007.07.012_bib6","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1128\/AAC.34.12.2392","article-title":"Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin","volume":"34","author":"Greenberg","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl.","key":"10.1016\/j.jinf.2007.07.012_bib7","first-page":"9","article-title":"Teicoplanin in the treatment of bone and joint infections. Teicoplanin Bone and Joint Cooperative Study Group","volume":"567","author":"LeFrock","year":"1992","journal-title":"USA. Eur J Surg"},{"key":"10.1016\/j.jinf.2007.07.012_bib8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ehj.2003.11.008","article-title":"Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the Task Force on Infective Endocarditis of the European Society of Cardiology","volume":"25","author":"Horstkotte","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jinf.2007.07.012_bib9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/BF02276052","article-title":"Use of teicoplanin in community medicine","volume":"13","author":"Wilson","year":"1994","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2007.07.012_bib10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0924-8579(99)00006-0","article-title":"The role of glycopeptide antibiotics in the treatment of infective endocarditis","volume":"12","author":"Gruneberg","year":"1999","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jinf.2007.07.012_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00003088-200039030-00001","article-title":"Clinical pharmacokinetics of teicoplanin","volume":"39","author":"Wilson","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jinf.2007.07.012_bib12","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/jac\/45.6.835","article-title":"Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome","volume":"45","author":"Harding","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2007.07.012_bib13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s10156-006-0446-Y","article-title":"Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level","volume":"12","author":"Sato","year":"2006","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jinf.2007.07.012_bib14","first-page":"21","article-title":"Comparative safety of teicoplanin and vancomycin","volume":"12","author":"Wood","year":"2000","journal-title":"J\u00a0Chemother"},{"key":"10.1016\/j.jinf.2007.07.012_bib15","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/jac\/dkg147","article-title":"Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose","volume":"51","author":"Pea","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2007.07.012_bib16","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/S0399-077X(04)90084-4","article-title":"Adequate use of teicoplanin in bone and joint infections","volume":"34","author":"Senneville","year":"2004","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.jinf.2007.07.012_bib17","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1128\/AAC.48.7.2394-2399.2004","article-title":"Randomized comparison of serum teicoplanin concentrations following daily or alternate daily dosing in healthy adults","volume":"48","author":"Rouveix","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2007.07.012_bib18","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/jac\/46.6.931","article-title":"Susceptibility of gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. The Linezolid Study Group","volume":"46","author":"Henwood","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2007.07.012_bib19","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/1120009X.2000.11782315","article-title":"Teicoplanin in the treatment of serious infection","volume":"12","author":"Schaison","year":"2000","journal-title":"J Chemother"},{"key":"10.1016\/j.jinf.2007.07.012_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s101560050005","article-title":"Teicoplanin in the treatment of bone and joint infections: an open study","volume":"5","author":"LeFrock","year":"1999","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jinf.2007.07.012_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijantimicag.2003.09.017","article-title":"Synergistic activity of vancomycin and teicoplanin alone and in combination with streptomycin against Enterococcus faecalis strains with various vancomycin susceptibilities","volume":"23","author":"Babalola","year":"2004","journal-title":"J Antimicrob Agents"},{"key":"10.1016\/j.jinf.2007.07.012_bib22","first-page":"669","article-title":"Synergy study of vancomycin or teicoplanin plus gentamicin against enterococci, Staphylococcus aureus and coagulase negative staphylococci by time-kill method","volume":"74","author":"Thamlikitkul","year":"1991","journal-title":"J\u00a0Med Assoc Thai"},{"key":"10.1016\/j.jinf.2007.07.012_bib23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/jac\/42.2.233","article-title":"Efficacy and safety of teicoplanin plus rifampicin in the treatment of bacteraemic infections caused by Staphylococcus aureus","volume":"42","author":"Yzerman","year":"1998","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2007.07.012_bib24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s100960000299","article-title":"Glycopeptide resistance in coagulase-negative staphylococci","volume":"19","author":"Biavasco","year":"2000","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2007.07.012_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jac\/21.suppl_A.93","article-title":"Teicoplanin in the treatment of infections caused by coagulase-negative staphylococci","volume":"21","author":"Harding","year":"1998","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2007.07.012_bib26","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/jac\/dkl233","article-title":"In vitro susceptibility of Gram-positive pathogens to linezolid and teicoplanin and effect on outcome in critically ill patients","volume":"58","author":"Wilson","year":"2006","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445307007025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445307007025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T15:31:41Z","timestamp":1758987101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445307007025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["S0163445307007025"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2007.07.012","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Teicoplanin levels in bone and joint infections: Are standard doses subtherapeutic?","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2007.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 The British Infection Society. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}